2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cooper, A. C. Articles by Macdougall, I. C. Search for Related Content PubMed PubMed Citation Articles by Cooper, A. C. Articles by Macdougall, I. C.

Increased Expression of Erythropoiesis Inhibiting Cytokines (IFN-, TNF-, IL-10, and IL-13) by T Cells in Patients Exhibiting a Poor Response to Erythropoietin Therapy

Angela C. Cooper^*,, Ashraf Mikhail^*, Mark W. Lethbridge, D. Michael Kemeny and Iain C. Macdougall^*

Departments of *Renal Medicine and Immunology, GKT School of Medicine, King’s College Hospital, London, UK.

Correspondence to Dr. Angela Cooper, Department of Renal Medicine, GKT School of Medicine, Bessemer Road, London SE5 9PJ, United Kingdom. Phone: 44-207-346-3582; Fax: 44-207-346 3710;

ABSTRACT. Resistance to recombinant human erythropoietin occurs in a small but important proportion of hemodialysis patients. This may be due to increased immune activation because pro-inflammatory cytokines inhibit erythropoiesis in vitro. Using FACScan flow cytometry, the proportion of PMA/ionomycin-stimulated T cells expressing cytokines ex vivo was compared in 18 poor responders to erythropoietin, 14 good responders to erythropoietin, and 14 normal controls. CD4⁺ T cells from poor responders expressed more interferon- (IFN-; 19 ± 6%) compared with good responders (11 ± 6%, P < 0.001) and controls (12 ± 6%, P < 0.01). Similarly, CD4⁺ T cells from poor responders expressed more tumor necrosis factor- (TNF-; poor responders: 51 ± 19% versus good responders: 27 ± 15% [P < 0.01] and controls: 30 ± 19% [P < 0.01]). CD4⁺ expression of IL-10 was also enhanced (poor responders: 1.6 ± 1.1% versus good responders: 0.7 ± 0.6% [P < 0.05] and controls: 0.5 ± 0.2% [P < 0.01]). Likewise, CD4⁺ expression of interleukin-13 (IL-13) was increased (poor responders: 4.4 ± 4.2% versus good responders: 1.6 ± 1.7% [P < 0.05] and controls: 1.6 ± 1.5% [P < 0.05]). CD8⁺ T cells from poor responders also showed enhanced expression of cytokines. For IFN-, poor responder expression was 48 ± 20% compared with 31 ± 17% (P < 0.05) for good responders and 23 ± 15% (P < 0.01) for controls. TNF- expression for poor responders was 41 ± 21% versus 25 ± 14% for good responders (P < 0.05) and 21 ± 15% for controls (P < 0.01). IL-10 expression for poor responders was 2.0 ± 1.2% (good responders: 0.7 ± 0.6% [P < 0.01]; controls: 0.5 ± 0.2% [P < 0.001]). These data indicate that T cells from poor responders are in an enhanced activation state possibly as a result of chronic inflammation. In the absence of any other cause (such as iron deficiency), the overproduction of cytokines may account for hyporesponsiveness to erythropoietic therapy in patients with renal failure. E-mail: angela.redrup@kcl.ac.uk

This article has been cited by other articles:

				M. Chonchol, G. Lippi, M. Montagnana, M. Muggeo, and G. Targher Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2879 - 2883. [Abstract] [Full Text] [PDF]

				G. M. E. Matta, S. Battaglio, C. DiBello, P. Napoli, C. Baldi, G. Ciccone, M. Coscia, M. Boccadoro, and M. Massaia Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma Clin. Cancer Res., September 15, 2007; 13(18): 5348 - 5354. [Abstract] [Full Text] [PDF]

				A. S. Goldfarb-Rumyantzev, J. F. Hurdle, B. C. Baird, G. Stoddard, Z. Wang, J. D. Scandling, L. L. Barenbaum, and A. K. Cheung The role of pre-emptive re-transplant in graft and recipient outcome Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1355 - 1364. [Abstract] [Full Text] [PDF]

				K.-R. Koh, M. Janz, M. Y. Mapara, B. Lemke, D. Stirling, B. Dorken, M. Zenke, and S. Lentzsch Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis Blood, May 15, 2005; 105(10): 3833 - 3840. [Abstract] [Full Text] [PDF]

				G. Weiss and L. T. Goodnough Anemia of Chronic Disease N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023. [Full Text] [PDF]

				A. Cooper, A. Mikhail, M. W. Lethbridge, D. M. Kemeny, and I. C. Macdougall Pentoxifylline Improves Hemoglobin Levels in Patients with Erythropoietin-resistant Anemia in Renal Failure J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1877 - 1882. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673